Affimed reports data from mid-stage study of its lymphoma treatment
by
Contributor since / Followers
Contributor since / Followers
2 weeks ago
- Affimed N.V. announced data from phase 2 study of the combination of acimtamig with Artiva Biotherapeutics’ allogeneic NK cell AlloNK in patients with relapsed/refractory classical hodgkin lymphoma.
- Acimtamig in combination with AlloNK demonstrated a high overall response rate of 86% with complete response of 55%.
- Source: Press Release